Swiss Medica Inc., Innovative Products That Improve Peoples' Lives

8/17/2004 8:21:32 AM ET

SWISS MEDICA ANNOUNCES CANADAPHARMACY.COM LAUNCH

Stock Symbol: OTC BB: SWME

August 17, 2004

SWISS MEDICA ANNOUNCES CANADAPHARMACY.COM LAUNCH

Toronto, Canada – Grant Johnson, President and COO of Swiss Medica, is pleased to announce the online and

direct sales launch of the Company’s O24 Essential Oil Pain Neutralizer product with one of the leading

International Mail Order Pharmacies, CanadaPharmacy.com.

CanadaPharmacy.com sells more than 4,000 prescription and non-prescription products to a customer base of

over 250,000 clients around the world. CanadaPharmacy is a fully-licensed Canadian pharmacy targeting USA

and international customers. CanadaPharmacy is accredited by CIPA (Canadian International Pharmacy

Association). As a leading mail order pharmacy, CanadaPharmacy is recognized for its competitive pricing, low

shipping costs, excellent customer service support and extensive product lines.

Grant Johnson said, “I am delighted that CanadaPharmacy placed the O24 Essential Oil Pain Neutralizer product

at the top of both its pain relief products and pain relief rubs listings. We are excited by the immediate sales the

Company has already received. Given CanadaPharmacy's ability to market a product to a specific group of

clients that suffer from an ailment, we anticipate a higher than usual conversion rate with the launch of the O24

sampling program in the near term.”

CanadaPharmacy.com’s Rob Julien, Product Development Manager said “I am excited about the opportunity to

introduce O24 to our customers. The product will certainly help many people that suffer from chronic pain, just

as it has helped me.”

About Swiss Medica Inc.

Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our

market share through focused distribution strategies in multiple sales channels. Swiss Medica’s mission is to be

a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please

visit our websites at www.swissmedica.com and

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the

United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking

statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close

transactions being contemplated, risks related to international sales and potential foreign currency exchange

fluctuations, continued acceptance of Swiss Medica’s products, increased levels of competition, technological

changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica’s

periodic reports filed with the United States Securities and Exchange Commission and other regulatory

authorities.

Investor Relations Contact:

David Jones

Swiss Medica Inc.

1 866 485 4243